

4.1.3. Număr de citări în reviste de specialitate cotate ISI¹

ANUL 2007			
Denumire Articol	Autori	Revista	Total citari 2005-2007
<u>Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children</u>	Balli, F., Bergamini, B., <u>Calistru, P.</u> , Ciofu, E.P., Domenici, R., Doros, G., Dragomir, D., Gherghina, I., Iordachescu, F., Murgoci, G., Orasanu, D., Plesca, D., Vaccaro, A., Assereto, R.	<u>International Journal of Clinical Pharmacology and Therapeutics</u> , Volume 45, Issue 1, January 2007, Pages 16-22	1
1. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: A 15-day, prospective, parallel, open-label, pilot study	<u>Crisafulli, E.</u> , <u>Coletti, O.</u> , <u>Costi, S.</u> , <u>Zanasi, E.</u> , <u>Lorenzi, C.</u> , <u>Lucic, S.</u> , <u>Fabbri, L.M.</u> , (...), <u>Clini, E.M.</u>	<i>Clinical Therapeutics</i> 29 (9), pp. 2001-2009	2007
ANUL 2004			
<u>Allele frequencies of 13 short tandem repeat (STR) loci in the Romanian population</u>	Barbarii, L.E., Rolf, B., Constantinescu, C., Hohoff, C., <u>Calistru, P.</u> , Dermengiu, D.	<u>Forensic Science International</u> Volume 141, Issue 2-3, 10 May 2004, Pages 171-174	9
1. Genetic STRs variation in a large population from Tuscany (Italy)	<u>Carboni, I.</u> , <u>Nutini, A.L.</u> , <u>Porfirio, B.</u> , <u>Genuardi, M.</u> , <u>Ricci, U.</u>	<i>Forensic Science International: Genetics</i> 1 (3-4), pp. e10-e11	2007
2. STR allele profile in forensic identification [Utilizarea profilului alelelor STR în identificarea originii persoanelor]	<u>Anghel, A.</u> , <u>Marian, C.</u> , <u>Samoila, C.</u> , <u>Lenghel, F.</u> , <u>Sfrijan, F.</u>	<i>Romanian Journal of Legal Medicine</i> 15 (3), pp. 234-236	2007
3. STR data for the 15 AmpFISTR identifier loci in the Western Romanian population	<u>Marian, C.</u> , <u>Anghel, A.</u> , <u>Bel, S.M.</u> , <u>Ferencz, B.K.</u> , <u>Ursoniu, S.</u> , <u>Dressler, M.</u> , <u>Popescu, O.</u> , <u>Budowle, B.</u>	<i>Forensic Science International</i> 170 (1), pp. 73-75	2007
4. Population data on the 11 STR loci in the Upper Silesia (Poland)	<u>Raczek, E.</u>	<i>Forensic Science International</i> 168 (1), pp. 68-72	2007
5. Population genetic study in two Transylvanian populations using forensically informative autosomal and Y-chromosomal STR markers	<u>Egyed, B.</u> , <u>Füredi, S.</u> , <u>Padar, Z.</u>	<i>Forensic Science International</i> 164 (2-3), pp. 257-265	2006

¹ Sunt excluse autocitările.

6. Mutations or exclusion: An unusual case in paternity testing	<u>Junge, A.</u> , <u>Brinkmann, B.</u> , <u>Fimmers, R.</u> , <u>Madea, B</u>	International Journal of Legal Medicine 120 (6), pp. 360-363	2006
7. Analysis of the population heterogeneity in Hungary using fifteen forensically informative STR markers	<u>Egyed, B.</u> , <u>Füredi, S.</u> , <u>Angyal, M.</u> , <u>Balogh, I.</u> , <u>Kalmar, L.</u> , <u>Padar, Z.</u>	Forensic Science International 158 (2-3), pp. 244-249	2006
8. Allele frequencies for 15 STR loci in a population from the Republic of Macedonia	<u>Jakovski, Z.</u> , <u>Nikolova, K.</u> , <u>Furac, I.</u> , <u>Masic, M.</u> , <u>Janeska, B.</u> , <u>Kubat, M.</u>	International Journal of Legal Medicine 120 (1), pp. 53-55	2006
9. Population genetics of the d19s433 locus in the northern Poland	<u>Wysocka, J.</u> , <u>Kapińska, E.</u> , <u>Repała, K.</u> , <u>Szczerkowska, Z.</u> , <u>Cybulska, L.</u>	Annales Academiae Medicae Gedanensis 35, pp. 181-185	2005
ANUL 2003			
<u>Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC</u>	Vastagh, E., Kuna, P., <u>Calistru, P.</u> , Bogdan, M.A.	Respiratory Medicine Volume 97, Issue SUPPL. D, November 2003, Pages S20-S28	8
1. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler® in adolescents and adults with asthma	<u>Morice, A.H.</u> , <u>Hochmuth, L.</u> , <u>Ekelund, J.</u> , <u>Thorén, A.</u> , <u>Puterman, A.S.</u>	<i>Pulmonary Pharmacology and Therapeutics</i> Volume 21, Issue 1, February 2008, Pages 32-39	2008
2. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology	<u>Acerbi, D.</u> , <u>Brambilla, G.</u> , <u>Kottakis, I.</u>	<i>Pulmonary Pharmacology and Therapeutics</i> 20 (3), pp. 290-303	2007
3. Short-term growth and adrenal function in children with asthma treated with inhaled beclomethasone dipropionate hydrofluoroalkane-134a	<u>Wolthers, O.D.</u>	<i>Pediatric Allergy and Immunology</i> 17 (8), pp. 613-619	2006
4. Systemic activity of inhaled hydrofluoroalkane-134a metered dose inhaler with beclomethasone dipropionate in children with asthma	<u>Wolthers, O.D.</u>	<i>Pediatric Asthma, Allergy and Immunology</i> 19 (3), pp. 172-179	2006
5. The greenhouse effect, Montreal Protocol and modern treatment of asthma - New types of inhalers - A systematic review and meta-analysis of randomised controlled trials about	<u>Macioch, T.</u> , <u>Winiarski, M.</u> , <u>Wardyn, K.A.</u>	<i>Family Medicine and Primary Care Review</i> 8 (3), pp. 994-996	2006

application of Modulite® technology in the treatment of asthma			
6. Modulite®: A simple solution to a difficult problem	<u>Lewis, D.A., Ganderton, D., Meakin, B.J., Brambilla, G.</u>	<i>Family Medicine and Primary Care Review</i> 8 (3), pp. 994-996	2005
7. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 µg) of formoterol-HFA (pMDI) vs. those of a dose level (24 µg) of formoterol-DPI (Foradil®/Aerolizer™) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients	<u>Bousquet, J., Guenolé, E., Duvauchelle, T., Vicaut, E., Lefrançois, G.</u>	<i>Respiration</i> 72 (SUPPL. 1), pp. 3-5	2005
8. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 µg) of formoterol-HFA (pMDI) vs. those of a dose level (24 µg) of formoterol-DPI (Foradil®/Aerolizer™) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients	<u>Molimard, M., Guenolé, E., Duvauchelle, T., Vicaut, E., Lefrançois, G.</u>	<i>Respiration</i> 72 (SUPPL. 1), pp. 13-19	2005
<u>Clinical manifestations in the West Nile virus outbreak</u>	Ceausu, E., Erşcoiu, S., <u>Calistru, P.</u> , Ispas, D., Dorobat, O., Homos, M., Barbulescu, C., Cojocaru, I., Simion, C.V., Cristea, C., Oprea, C., Dumitrescu, C., Duiculescu, D., Marcu, I., Mociornita, C., Stoicev, T., Zolotuşca, I., Calomfirescu, C., Rusu, R., Hodrea, R., Geamai, S., Paun, L.	<i>Romanian Journal of Virology</i> Volume 48, Issue 1-4, January 1997, Pages 3-11	11
1. Vaccination against mosquito borne viral infections: Current status	<u>Wiwanitkit, V.</u>	<i>Iranian Journal of Immunology</i> 4 (4), pp. 186-196	2007
2. The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection	<u>Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, DavedH.</u>	<i>Cell Host and Microbe</i> 1 (2), pp. 135-145	2007

	<u>Diamond, M.S.</u>		
3. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis	<u>Samuel, M.A., Morrey, J.D., Diamond, M.S.</u>	Journal of Virology 81 (6), pp. 2614-2623	2007
4. Pathogenesis of West Nile virus infection: A balance between virulence, innate and adaptive immunity, and viral evasion	<u>Samuel, M.A., Diamond, M.S.</u>	Journal of Virology 80 (19), pp. 9349-9360	2006
5. West Nile virus; ecology and epidemiology of an emerging pathogen in Colombia	<u>Berrocal, L., Peña, J., González, M., Mattar, S.</u>	Revista de Salud Publica 8 (2), pp. 218-228	2006
6. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons	<u>Samuel, M.A., Whitby, K., Keller, B.C., Marri, A., Barchet, W., Williams, B.R.G., Silverman, R.H., (...), Diamond, M.S.</u>	Journal of Virology 80 (14), pp. 7009-7019	2006
7. West Nile virus: Epidemiology and clinical features of an emerging epidemic in the United States	<u>Hayes, E.B., Gubler, D.J.</u>	Annual Review of Medicine 57, pp. 181-194	2006
8. Skin manifestations of West Nile Virus infection	<u>Del Giudice, P., Schuffenecker, I., Zeller, H., Grelier, M., Vandenbos, F., Dellamonica, P., Counillon, E.</u>	Dermatology 211 (4), pp. 348-350	2005
9. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival	<u>Samuel, M.A., Diamond, M.S.</u>	Journal of Virology 79 (21), pp. 13350-13361	2005
10. The emergence of West Nile virus during a large outbreak in Illinois in 2002	<u>Huhn, G.D., Austin, C., Langkop, C., Kelly, K., Lucht, R., Lampman, R., Novak, R., (...), Dworkin, M.S.</u>	American Journal of Tropical Medicine and Hygiene 72 (6), pp. 768-776	2005
11. West Nile Virus (WNV): Implication and generalities in blood transfusion	<u>Gallian, P., De Lamballerie, X., De Micco, P., Andreu, G.</u>	Transfusion Clinique et Biologique 12 (1), pp. 11-17	2005
ANUL 2002			
<u>Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: A phase III randomised trial</u>	Grigorescu, A.C, Draghici, I.N, Nitipir, C , Gutulescu, N, Corlan, E	<u>Lung Cancer</u> 37 (1), pp. 9-14	18

1. A meta-analysis of 1 randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer	<u>Jiang, J., Liang, X., Zhou, X., Huang, R., Chu, Z.</u>	Lung Cancer 57 (3), pp. 348-358	2007
2. Role of gemcitabine in the treatment of non-small cell lung cancer (NSCLC)	<u>Babicková, L., Skříčková, J., Roubec, J.</u>	Studia Pneumologica et Phthiseologica 67 (2), pp. 76-89	2007
3. Clinical trials with oncolytic adenovirus in China	<u>Yu, W., Fang, H.</u>	Current Cancer Drug Targets 7 (2), pp. 141-148	2007
4. Development of new first-line therapeutic options for non-small-cell lung cancer	<u>Crinò, L., Foglietta, J., Hamzaj, A.</u>	Lung Cancer 54 (SUPPL. 2), pp. S19-S24	2006
5. Role of non-taxane-containing chemotherapy in advanced non-small cell lung cancer	<u>Bergqvist, M., Sörenson, S., Brattström, D., Mok, T., Henriksson, R.</u>	American Journal of Cancer 5 (4), pp. 223-244	2006
6. A meta-analysis of the curative effects of carboplastin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer	<u>Jiang, J.-W., Liang, X.-H., Zhou, X.-L., Huang, R.-F.</u>	National Medical Journal of China 86 (37), pp. 2615-2620	2006
7. Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer	<u>Schuette, W., Blankenburg, T., Schneider, C.-P., von Weikersthal, L.F., Guetz, S., Laier-Groeneveld, G., Virchow, J.C., (...), Reck, M.</u>	Clinical Lung Cancer 8 (2), pp. 135-139	2006
8. Non-small cell lung cancer. Palliative chemotherapy in stage IV non-small cell lung cancer and in patients with comorbidity	<u>Reck, M., Deppermann, K.M., Gatzemeier, U., Niederle, N.</u>	Onkologie 12 (8), pp. 761-768	2006
9. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: A randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)	<u>Boaton, R., Lorigan, P., Anderson, H., Baka, S., Ashcroft, L., Nicolson, M., O'Brien, M., (...), Thatcher, N.</u>	Annals of Oncology 17 (7), pp. 1111-1119	2006
10. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer	<u>Blackstock, A.W., Ho, C., Butler, J., Fletcher-Steede, J., Case, L.D., Hinson, W., Miller, A.A.</u>	Journal of Thoracic Oncology 1 (5), pp. 434-440	2006
11. Phase II study of PKC- α antisense oligonucleotide	<u>Ritch, P., Rudin, C.M., Bitran, J.D.,</u>	Lung Cancer 52 (2), pp. 173-180	2006

aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer	<u>Edelman, M.J., Makalinao, A., Irwin, D., Lilienbaum, R., (...), John, W.J.</u>		
12. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer. GFPC 99-01 study (Groupe français de pneumo-cancérologie)	<u>Thomas, P., Robinet, G., Gouva, S., Fournel, P., Léna, H., Le Caer, H., Perol, M., (...), Kleisbauer, J.P.</u>	Lung Cancer 51 (1), pp. 105-114	2006
13. The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer	<u>Cullen, M.</u>	Lung Cancer 50 (SUPPL. 1), pp. S5-S7	2005
14. Treatment of the unresectable non small cell lung carcinoma	<u>Špásová, I.</u>	Casopis Lekaru Ceskych 144 (9), pp. 602-612	2005
15. Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer	<u>Beslija, S., Dizdarević, Z., Lomigorić, J., Zutić, H., Musanović, M., Mehić, B., Cardjić, A., (...), Obralić, N.</u>	Journal of B.U.ON. 10 (3), pp. 347-355	2005
16. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)	<u>Reck, M.</u>	Anticancer Research 25 (3 A), pp. 1501-1506	2005
17. Gemcitabine in first-line therapy of locally advanced and/or metastatic non-small cell lung cancer (NSCLC): Review of the results of randomized phase III studies	<u>Leschinger, M.I., Helsberg, K., Langer, F., Schuette, W.H.-W.</u>	Onkologie 28 (SUPPL. 1), pp. 1-28	2005
18. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes	<u>Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., (...), Schiller, J.H.</u>	Lung Cancer 47 (1), pp. 69-80	2005
TOTAL CITARI 2005-2007 = 47			

4.1.3. Numar de citari
Total punctaj cap. 4.1.3

47 x 5 = 235
235 puncte